Information on Antipsychotics
FDA ALERT [6/16/2008]: FDA is notifying healthcare professionals that both conventional and atypical antipsychotics are associated with an increased risk of mortality in elderly patients treated for dementia-related psychosis.
In April 2005, FDA notified healthcare professionals that patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death. Since issuing that notification, FDA has reviewed additional information that indicates the risk is also associated with conventional antipsychotics.
Antipsychotics are not indicated for the treatment of dementia-related psychosis.
This information reflects FDA's current analysis of data available to FDA concerning this drug. FDA intends to update this when additional information or analyses become available.
- Healthcare Professional Information
- FDA News: FDA Requests Boxed Warnings on Older Class of Antipsychotic Drugs
- Conventional Antipsychotic Drugs
- Compazine (prochlorperazine)
- Haldol (haloperidol)
- Loxitane (loxapine)
- Mellaril (thioridazine)
- Moban (molindrone)
- Navane (thithixene)
- Orap (pimozide)
- Prolixin (fluphenazine)
- Stelazine (trifluoperazine)
- Thorazine (chlorpromazine)
- Trilafon (perphenazine)
Report Adverse Events to MedWatch
Back
to Top
Back to Drug Information
PDF requires the free Adobe Acrobat Reader
Date created: June 16, 2008, updated June 17, 2008 |